National Bank of Canada
CARM

National Bank of Canada’s Carisma Therapeutics CARM Stock Holding History

National Bank of Canada’s Portfolio CARM Stock Details CARM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-50
Closed -$13 – 2909
2025
Q3 		$13 Hold
50
– – ﹤0.01% 2812
2025
Q2 		$20 Hold
50
– – ﹤0.01% 2922
2025
Q1 		$16 Hold
50
– – ﹤0.01% 2784
2024
Q4 		$21 Sell
50
-115
-70% -$95 ﹤0.01% 2851
2024
Q3 		$162 Buy
165
+115
+230% +$125 ﹤0.01% 2538
2024
Q2 		$83 Hold
50
– – ﹤0.01% 2640
2024
Q1 		$73 Hold
50
– – ﹤0.01% 2677
2023
Q4 		$142 Hold
50
– – ﹤0.01% 2649
2023
Q3 		$212 Hold
50
– – ﹤0.01% 2693
2023
Q2 		$438 Hold
50
– – ﹤0.01% 2626
2023
Q1 		$153 Hold
50
– – ﹤0.01% 2649
2022
Q4 		$605 Hold
50
– – ﹤0.01% 2632
2022
Q3 		$0 Sell
50
-61
-55% -$831 ﹤0.01% 2708
2022
Q2 		$2K Hold
111
– – ﹤0.01% 2585
2022
Q1 		$1K Hold
111
– – ﹤0.01% 2766
2021
Q4 		$2K Buy
+111
New +$2.23K ﹤0.01% 2667

Other funds holding CARM

MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
EF
Empowered Funds Havertown, Pennsylvania $15.7B AUM 34.02% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
UBP
Union Bancaire Privee Geneva 1, Switzerland $9.16B AUM 31.4% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
OP
ORG Partners Roanoke, Indiana $568M AUM 24.16% 1-Year Est. Return

National Bank of Canada's CARM Position: Q4 2025 in Review

National Bank of Canada sold out of Carisma Therapeutics (CARM) in Q4 2025, closing a stake of 50 shares — an estimated $13 sold.

National Bank of Canada first reported a position in CARM in Q4 2021 and held it in 16 quarters. The position peaked at $2K in Q2 2022. 7 funds tracked by Wall St. Rank hold CARM as of Q4 2025.

  • National Bank of Canada reported no remaining Carisma Therapeutics position as of Q4 2025 after selling out during the quarter.
  • National Bank of Canada sold 50 Carisma Therapeutics shares in Q4 2025, an estimated $13.
  • National Bank of Canada first reported a position in Carisma Therapeutics in Q4 2021 and held it in 16 quarters.
  • National Bank of Canada's Carisma Therapeutics position peaked at $2K in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q4 2025.

Based on National Bank of Canada's 13F filing for Q4 2025, filed 17 Feb 2026.